Santhera Pharmaceuticals Holding AG (SWX:SANN)

Switzerland · Delayed Price · Currency is CHF

15.22

-0.52 (-3.30%)

Jul 10, 2026, 5:30 PM CET

Revenue by Segment

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Development and Commercialization of products for the treatment of Neuromuscular and Pulmonary Diseases	77.19M	39.12M	103.41M	7.47M	-1.60M
Development and Commercialization of products for the treatment of Neuromuscular and Pulmonary Diseases Growth	97.32%	-62.17%	1283.84%	-	-
Total	77.19M	39.12M	103.41M	7.47M	-1.60M
Total Growth	97.32%	-62.17%	1283.84%	-	-

Revenue by Geography

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Asia	6.52M	12.79M	1.92M	11.19M	-
Asia Growth	-49.02%	565.96%	-82.83%	-	-
North America	46.29M	11.35M	98.09M	-	-
North America Growth	307.67%	-88.43%	-	-	-
Europe	24.38M	14.97M	3.40M	-3.72M	-1.60M
Europe Growth	62.83%	340.04%	-	-	-
Total	77.19M	39.12M	103.41M	7.47M	-1.60M
Total Growth	97.32%	-62.17%	1283.84%	-	-